vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Finwise Bancorp (FINW). Click either name above to swap in a different company.
Finwise Bancorp is the larger business by last-quarter revenue ($42.7M vs $21.9M, roughly 1.9× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs 6.4%, a 0.8% gap on every dollar of revenue. Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 47.0%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Finwise Bancorp is a U.S.-based financial holding company that operates primarily through its community banking subsidiary. It offers a full suite of retail and commercial financial services, including deposit accounts, personal loans, mortgage products, small business financing, and wealth management solutions, serving local retail consumers and small to medium-sized business clients across its regional operating markets.
CUE vs FINW — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $42.7M |
| Net Profit | $1.6M | $2.7M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | — |
| Net Margin | 7.2% | 6.4% |
| Revenue YoY | 1292.3% | — |
| Net Profit YoY | 116.7% | — |
| EPS (diluted) | $0.05 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $42.7M | ||
| Q4 25 | $21.9M | $46.9M | ||
| Q3 25 | $2.1M | $36.7M | ||
| Q2 25 | $3.0M | $25.1M | ||
| Q1 25 | $421.0K | $22.1M | ||
| Q4 24 | $1.6M | $21.1M | ||
| Q3 24 | $3.3M | $20.8M | ||
| Q2 24 | $2.7M | $19.8M |
| Q1 26 | — | $2.7M | ||
| Q4 25 | $1.6M | $3.9M | ||
| Q3 25 | $-7.4M | $4.9M | ||
| Q2 25 | $-8.5M | $4.1M | ||
| Q1 25 | $-12.3M | $3.2M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | $-8.7M | $3.5M | ||
| Q2 24 | $-10.2M | $3.2M |
| Q1 26 | — | — | ||
| Q4 25 | 9.0% | 11.7% | ||
| Q3 25 | -353.4% | 17.5% | ||
| Q2 25 | -292.3% | 21.7% | ||
| Q1 25 | -2921.4% | 20.1% | ||
| Q4 24 | — | 17.5% | ||
| Q3 24 | -264.2% | 22.2% | ||
| Q2 24 | -390.6% | 21.1% |
| Q1 26 | — | 6.4% | ||
| Q4 25 | 7.2% | 8.4% | ||
| Q3 25 | -346.6% | 13.3% | ||
| Q2 25 | -287.1% | 16.3% | ||
| Q1 25 | -2911.4% | 14.4% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | -259.6% | 16.6% | ||
| Q2 24 | -382.7% | 16.1% |
| Q1 26 | — | $0.20 | ||
| Q4 25 | $0.05 | $0.27 | ||
| Q3 25 | $-0.07 | $0.34 | ||
| Q2 25 | $-0.09 | $0.29 | ||
| Q1 25 | $-0.17 | $0.23 | ||
| Q4 24 | — | $0.19 | ||
| Q3 24 | $-0.17 | $0.25 | ||
| Q2 24 | $-0.20 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $196.6M |
| Total Assets | $42.2M | $899.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $27.1M | $163.4M | ||
| Q3 25 | $11.7M | $105.6M | ||
| Q2 25 | $27.5M | $90.1M | ||
| Q1 25 | $13.1M | $120.3M | ||
| Q4 24 | $22.5M | $109.2M | ||
| Q3 24 | $32.4M | $85.8M | ||
| Q2 24 | $30.0M | $89.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — |
| Q1 26 | — | $196.6M | ||
| Q4 25 | $26.4M | $193.2M | ||
| Q3 25 | $13.2M | $187.8M | ||
| Q2 25 | $18.2M | $182.0M | ||
| Q1 25 | $6.6M | $177.4M | ||
| Q4 24 | $17.5M | $173.7M | ||
| Q3 24 | $25.4M | $170.4M | ||
| Q2 24 | $21.6M | $165.8M |
| Q1 26 | — | $899.4M | ||
| Q4 25 | $42.2M | $977.1M | ||
| Q3 25 | $31.6M | $899.9M | ||
| Q2 25 | $40.7M | $842.5M | ||
| Q1 25 | $22.3M | $804.1M | ||
| Q4 24 | $32.2M | $746.0M | ||
| Q3 24 | $44.8M | $683.0M | ||
| Q2 24 | $42.3M | $617.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-1.1M | $-28.4M | ||
| Q3 25 | $-9.0M | $3.5M | ||
| Q2 25 | $-3.4M | $-18.3M | ||
| Q1 25 | $-8.2M | $-21.6M | ||
| Q4 24 | $-36.3M | $-15.0M | ||
| Q3 24 | $-7.5M | $-9.8M | ||
| Q2 24 | $-10.0M | $-7.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-28.6M | ||
| Q3 25 | — | $3.4M | ||
| Q2 25 | $-3.4M | $-19.8M | ||
| Q1 25 | $-8.3M | $-23.3M | ||
| Q4 24 | $-36.4M | $-16.1M | ||
| Q3 24 | $-7.5M | $-13.4M | ||
| Q2 24 | $-10.0M | $-7.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | -61.1% | ||
| Q3 25 | — | 9.4% | ||
| Q2 25 | -116.5% | -79.0% | ||
| Q1 25 | -1976.7% | -105.3% | ||
| Q4 24 | -2309.3% | -76.0% | ||
| Q3 24 | -225.7% | -64.3% | ||
| Q2 24 | -376.2% | -38.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.9% | 5.8% | ||
| Q1 25 | 35.6% | 7.4% | ||
| Q4 24 | 4.2% | 5.1% | ||
| Q3 24 | 0.0% | 17.2% | ||
| Q2 24 | 0.4% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | -0.68× | -7.26× | ||
| Q3 25 | — | 0.71× | ||
| Q2 25 | — | -4.48× | ||
| Q1 25 | — | -6.78× | ||
| Q4 24 | — | -5.37× | ||
| Q3 24 | — | -2.84× | ||
| Q2 24 | — | -2.39× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
FINW
| Net Interest Income | $28.1M | 66% |
| Noninterest Income | $14.6M | 34% |
